Skip to main
ALLR

Allarity Therapeutics (ALLR) Stock Forecast & Price Target

Allarity Therapeutics (ALLR) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allarity Therapeutics Inc. is currently perceived to have an attractive valuation, as evidenced by recent increases in price targets that suggest substantial potential for growth from its current share price. The company is advancing its lead product, stenoparib, which has demonstrated promising clinical outcomes, including a median overall survival surpassing 25 months for patients enrolled in its Phase 2 trial, highlighting its potential in addressing critical treatment gaps. This positive outlook is further supported by the company's innovative use of its Drug Response Predictor (DRP) technology to optimize patient selection, ultimately enhancing clinical efficacy and outcomes for patients with advanced recurrent ovarian cancer.

Bears say

Allarity Therapeutics is experiencing significant financial instability, highlighted by a net loss of $2.8 million, resulting in an earnings per share (EPS) of $(0.19), which slightly missed estimates of $(0.23). The company's ongoing financial losses raise concerns about balance sheet and liquidity risks, especially amid the inherent uncertainties of clinical trials and the potential failure to achieve regulatory approvals for its lead asset, stenoparib. Additionally, external factors such as market competition and shifting investor sentiment towards biotech stocks further exacerbate the challenges facing Allarity Therapeutics, contributing to a negative outlook on the company's stock.

Allarity Therapeutics (ALLR) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allarity Therapeutics (ALLR) Forecast

Analysts have given Allarity Therapeutics (ALLR) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Allarity Therapeutics (ALLR) has a Strong Buy consensus rating as of Mar 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allarity Therapeutics (ALLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.